Nivolumab

Drug Profile

Nivolumab

Alternative Names: Anti-PD-1 monoclonal antibody - Medarex/Ono; BMS-936558; MDX-1106; Nivolumab BMS; ono-0123; ONO-4538; Opdivo

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Medarex; Ono Pharmaceutical
  • Developer AIO Studien gGmbH; Bristol-Myers Squibb; Duke University Medical Center; Eli Lilly; Grupo Espanol Multidisciplinar de Melanoma; Incyte Corporation; Janssen Research & Development; Kyowa Hakko Kirin; Medarex; National Cancer Center (Tokyo); National Cancer Institute (USA); Nektar Therapeutics; Neon Therapeutics; Netherlands Cancer Institute; Ono Pharmaceutical; Pharmacyclics; Seattle Genetics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Hodgkin's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Registered Head and neck cancer; Hodgkin's disease; Urogenital cancer
  • Preregistration Gastric cancer
  • Phase III Glioblastoma; Hepatocellular carcinoma; Mesothelioma; Multiple myeloma; Oesophageal cancer; Ovarian cancer; Small cell lung cancer
  • Phase II Acute myeloid leukaemia; Breast cancer; Cancer; Carcinomatous meningitis; Cervical cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Myelodysplastic syndromes; Soft tissue sarcoma; Uterine cancer; Uveal melanoma
  • Phase I/II Bladder cancer; Colorectal cancer; Haematological malignancies; Non-Hodgkin's lymphoma; Rectal cancer; Solid tumours
  • Phase I Biliary cancer; Chronic myeloid leukaemia; Glioma; Hepatitis C

Most Recent Events

  • 13 Mar 2017 Bristol-Myers Squibb amends the clinical trial protocol for phase I/II trial in Solid tumours (Combination Therapy)
  • 09 Mar 2017 Bristol-Myers Squibb terminates a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA, Finland due to lack of efficacy in the short term acute phase (NCT02472977)
  • 06 Mar 2017 Bristol-Myers Squibb plans a phase III trial for Melanoma (Late-stage disease, Combination therapy, Monotherapy therapy) in USA, Australia, Belgium, Czech Republic, Hungary, Italy, New Zealand, Poland, Romania, Spain and United Kingdom (NCT03068455)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top